Non-viral nucleic acid therapeutics: Revolutionizing the landscape of atherosclerotic treatment
Atherosclerosis is an important pathological basis of several cardiovascular diseases and
viewed as a fundamental indicator for cardiovascular disease management. Gene therapy is …
viewed as a fundamental indicator for cardiovascular disease management. Gene therapy is …
Nanomedicine meets microRNA: current advances in RNA-based nanotherapies for atherosclerosis
S Gadde, KJ Rayner - Arteriosclerosis, thrombosis, and vascular …, 2016 - Am Heart Assoc
Cardiovascular disease (CVD) accounts for almost half of all deaths worldwide and has now
surpassed infectious disease as the leading cause of death and disability in developing …
surpassed infectious disease as the leading cause of death and disability in developing …
Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis
X Li, H Qi, W Cui, Z Wang, X Fu, T Li, H Ma, Y Yang… - Molecular Therapy, 2022 - cell.com
Cardiovascular disease (CVD) has overtaken infectious illnesses as the leading cause of
mortality and disability worldwide. The pathology that underpins CVD is atherosclerosis …
mortality and disability worldwide. The pathology that underpins CVD is atherosclerosis …
Scavenger receptor-targeted plaque delivery of microRNA-coated nanoparticles for alleviating atherosclerosis
Atherosclerosis treatments by gene regulation are garnering attention, yet delivery of gene
cargoes to atherosclerotic plaques remains inefficient. Here, we demonstrate that assembly …
cargoes to atherosclerotic plaques remains inefficient. Here, we demonstrate that assembly …
Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art
FV Lasemi, SH Aghaee-Bakhtiari, A Jalili… - Drug Discovery …, 2019 - Elsevier
Highlights•Nucleic acid-based technologies are emerging therapies for atherosclerosis.•
Antisense oligonucleotides, siRNAs, microRNAs and decoys can modulate lipids.•We …
Antisense oligonucleotides, siRNAs, microRNAs and decoys can modulate lipids.•We …
Nucleic acid–based therapies for atherosclerosis
P Mäkinen, AK Ruotsalainen… - Current atherosclerosis …, 2020 - Springer
Abstract Purpose of Review Atherosclerosis is characterized by accumulation of lipids and
chronic inflammation in medium size to large arteries. Recently, RNA-based antisense …
chronic inflammation in medium size to large arteries. Recently, RNA-based antisense …
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
U Makhmudova, E Steinhagen-Thiessen… - Cardiovascular …, 2024 - academic.oup.com
Nucleic acid-based therapies are being rapidly developed for prevention and management
of cardiovascular diseases (CVD). Remarkable advancements have been achieved in the …
of cardiovascular diseases (CVD). Remarkable advancements have been achieved in the …
Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases
L Jiao, Z Sun, Z Sun, J Liu, G Deng… - … in Bioengineering and …, 2024 - frontiersin.org
Gene therapy is a technique that rectifies defective or abnormal genes by introducing
exogenous genes into target cells to cure the disease. Although gene therapy has gained …
exogenous genes into target cells to cure the disease. Although gene therapy has gained …
Nucleic acid delivery to the vascular endothelium
M Reschke, AS Piotrowski-Daspit, JS Pober… - Molecular …, 2022 - ACS Publications
This Review examines the state-of-the-art in the delivery of nucleic acid therapies that are
directed to the vascular endothelium. First, we review the most important homeostatic …
directed to the vascular endothelium. First, we review the most important homeostatic …
Gene delivery nanoparticles to modulate angiogenesis
Angiogenesis is naturally balanced by many pro-and anti-angiogenic factors while an
imbalance of these factors leads to aberrant angiogenesis, which is closely associated with …
imbalance of these factors leads to aberrant angiogenesis, which is closely associated with …